The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.

Gudmundsdottir K; Ashworth A

doi:10.1038/sj.onc.1209874

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.

Gudmundsdottir K ¹,

Ashworth A

Affiliations

1. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, UK.
Authors
Gudmundsdottir K¹
(1 author)

Oncogene, 01 Sep 2006, 25(43):5864-5874
https://doi.org/10.1038/sj.onc.1209874 PMID: 16998501

Review

Abstract

The BRCA1 and BRCA2 proteins are important in maintaining genomic stability by promoting efficient and precise repair of double-strand breaks. The main role of BRCA2 appears to involve regulating the function of RAD51 in the repair by homologous recombination. BRCA1 has a broader role upstream of BRCA2, participating in various cellular processes in response to DNA damage. The DNA repair defect associated with mutations in BRCA1 or BRCA2 could be exploited to develop new targeted therapeutic approaches for cancer occurring in mutation carriers.

Full text links

Read article at publisher's site: https://doi.org/10.1038/sj.onc.1209874

References

Articles referenced by this article (119)

A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining.
Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, Feunteun J, Stoppa-Lyonnet D, Papadopoulo D
Oncogene, (9):1401-1410 2002
MED: 11857083
The proteasome: paradigm of a self-compartmentalizing protease.
Baumeister W, Walz J, Zuhl F, Seemuller E
Cell, (3):367-380 1998
MED: 9476896
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK
J Biol Chem, (31):23899-23903 2000
MED: 10843985
Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R . (1997). Hum Mol Genet 6: 53–58.
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R
Cell, (2):257-265 2000
MED: 10943845
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T
Nature, (7035):913-917 2005
MED: 15829966
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R
Mol Cell, (3):317-328 1998
MED: 9774970
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Cortez D, Wang Y, Qin J, Elledge SJ
Science, (5442):1162-1166 1999
MED: 10550055
Crackower MA, Scherer SW, Rommens JM, Hui CC, Poorkaj P, Soder S et al. (1996). Hum Mol Genet 5: 571–579.
Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2.
Daniels MJ, Wang Y, Lee M, Venkitaraman AR
Science, (5697):876-879 2004
MED: 15375219

Show 10 more references (10 of 119)

Citations & impact

Impact metrics

364

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/18183472

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/18183472

Article citations

Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Murray CE, Kornepati AVR, Ontiveros C, Liao Y, de la Peña Avalos B, Rogers CM, Liu Z, Deng Y, Bai H, Kari S, Padron AS, Boyd JT, Reyes R, Clark CA, Svatek RS, Li R, Hu Y, Wang M, Conejo-Garcia JR, [...] Curiel TJ
Mol Cancer, 23(1):242, 30 Oct 2024
Cited by: 0 articles | PMID: 39478560 | PMCID: PMC11523829
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali JA, Shenker S, Griffith J, McGuire M, Grasberger P, Mishina Y, Murray M, Dodson AE, Gannon H, Krall E, Hixon J, Chipumuro E, Sinkevicius K, Gokhale PC, [...] Wylie AA
Cancer Res, 84(20):3419-3434, 01 Oct 2024
Cited by: 0 articles | PMID: 39402989 | PMCID: PMC11474170
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer.
Jo SY, Lee JD, Won J, Park J, Kweon T, Jo S, Sohn J, Kim SI, Kim S, Park HS
iScience, 27(8):110469, 06 Jul 2024
Cited by: 0 articles | PMID: 39156639 | PMCID: PMC11326956
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.
Xie Y, Xiao D, Li D, Peng M, Peng W, Duan H, Yang X
Front Oncol, 14:1441222, 02 Aug 2024
Cited by: 0 articles | PMID: 39156700 | PMCID: PMC11327142
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.
Matuszczak M, Kiljańczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, Bryśkiewicz M, Cybulski C, Dębniak T, Gronwald J, Huzarski T, Lener M, Jakubowska A, Szwiec M, Stawicka-Niełacna M, Godlewski D, Prusaczyk A, Jasiewicz A, Kluz T, [...] Lubiński J
Antioxidants (Basel), 13(7):841, 14 Jul 2024
Cited by: 2 articles | PMID: 39061909 | PMCID: PMC11273827
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (364) article citations

Funding

Funders who supported this work.

Breast Cancer Now (1)

Breast Cancer Now Research Centre
Professor Mitchell Dowsett, Breakthrough Toby Robins Breast Cancer Research Centre
Grant ID: BREAST CANCER NOW RESEARCH CENTRE
621 publications

Search life-sciences literature (45,105,671 articles, preprints and more)

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.

Affiliations

Authors

Abstract

Full text links

References

A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining.

The proteasome: paradigm of a self-compartmentalizing protease.

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.

Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R . (1997). Hum Mol Genet 6: 53–58.

BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.

Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

Crackower MA, Scherer SW, Rommens JM, Hui CC, Poorkaj P, Soder S et al. (1996). Hum Mol Genet 5: 571–579.

Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.

Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer.

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.

Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Similar Articles

Therapeutic exploitation of tumor cell defects in homologous recombination.

Homologous repair of DNA damage and tumorigenesis: the BRCA connection.

Functions of BRCA1 and BRCA2 in the biological response to DNA damage.

BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.

Funding

Breast Cancer Now (1)

Breast Cancer Now Research Centre

Partnerships & funding

Search life-sciences literature (45,105,671 articles, preprints and more)

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.

Author information

Affiliations

Authors

Abstract

Full text links

References

Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R . (1997). Hum Mol Genet 6: 53–58.

Crackower MA, Scherer SW, Rommens JM, Hui CC, Poorkaj P, Soder S et al. (1996). Hum Mol Genet 5: 571–579.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Funding

Breast Cancer Now (1)﻿

Partnerships & funding

Breast Cancer Now (1)